利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.032 秒)

    Peroxisome proliferator activated receptor alpha agonists
    21.
    发明授权
    Peroxisome proliferator activated receptor alpha agonists 失效
    过氧化物酶体增殖物激活受体α激动剂

    公开(公告)号：US07205321B2

    公开(公告)日：2007-04-17

    申请号：US10495204

    申请日：2002-11-13

    申请人： Richard Duane Johnston ,  Nathan Bryan Mantlo ,  Richard Craig Thompson

    发明人： Richard Duane Johnston ,  Nathan Bryan Mantlo ,  Richard Craig Thompson

    IPC分类号： A61K31/4245 ,  C07D271/10

    CPC分类号： C07D271/113

    摘要： The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1–C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, and C3–C6 cycloalkylaryl-C0-2-alkyl; W is O or S; X is an optionally substituted C1–C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; Y is C, O, S, NH or a single bond; E is C(R3)(R4)A or A

    摘要翻译： 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐，溶剂合物和水合物，R1选自氢，取代或未取代的基团，其选自C 1 -C 8烷基，芳基-C 0-4 - 烷基，杂芳基-C 0-4 - 烷基和C 3 -C 6环烷基芳基-C 0-2 - 烷基; W为O或S; X是任选取代的C1-C5亚烷基连接体，其中连接体的一个碳原子可被O，NH或S取代; Y是C，O，S，NH或单键; E为C（R3）（R4）A或A

    PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS
    23.
    发明申请
    PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS 审中-公开
    过氧化物促进剂激活受体调节剂

    公开(公告)号：US20100099725A1

    公开(公告)日：2010-04-22

    申请号：US12522723

    申请日：2008-02-12

    申请人： Lance Allen Pfeifer ,  Tianwei Ma ,  Nathan Bryan Mantlo ,  Laura Frey Michael ,  Fese Mambo Mokube ,  Chahrzad Montrose-Rafizadeh

    发明人： Lance Allen Pfeifer ,  Tianwei Ma ,  Nathan Bryan Mantlo ,  Laura Frey Michael ,  Fese Mambo Mokube ,  Chahrzad Montrose-Rafizadeh

    IPC分类号： A61K31/4196 ,  C07D249/12 ,  A61P9/10

    CPC分类号： C07D401/06 ,  C07D249/12

    摘要： The present invention is directed to compounds of the structural Formula: wherein: R1 is H or —C1-C3 alkyl; R2 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, CH2—C═CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; provided that when R1 and R2 are each H, then R3 is selected from the group consisting of —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, —CH2—C═CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; or stereoisomers and pharmaceutically acceptable salts thereof.

    摘要翻译： 本发明涉及结构式的化合物：其中：R 1是H或-C 1 -C 3烷基; R 2选自-H，-C 1 -C 4烷基，-C 1 -C 3烷基-CF 3，苯基和吡啶基; 并且R 3选自-H，-C 1 -C 4烷基，-C 1 -C 3烷基-O-CH 3，-CH 2 - 环丙基，CH 2-C≡CH2，-CH 2 CH 2 - （2-F-苯基）， 和被1至2个氟取代的苯基; 条件是当R 1和R 2各自为H时，R 3选自-C 1 -C 4烷基，-C 1 -C 3烷基-O-CH 3，-CH 2 - 环丙基，-CH 2-C≡CH2，-CH 2 CH 2 - （2-F-苯基）和被1至2个氟取代的苯基; 或立体异构体及其药学上可接受的盐。